255 related articles for article (PubMed ID: 10100758)
41. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
Xu XF; Tang PZ; Cheng SJ
Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
[TBL] [Abstract][Full Text] [Related]
42. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer.
Stoehr R; Zietz S; Burger M; Filbeck T; Denzinger S; Obermann EC; Hammerschmied C; Wieland WF; Knuechel R; Hartmann A
Eur Urol; 2005 Jan; 47(1):58-63. PubMed ID: 15582250
[TBL] [Abstract][Full Text] [Related]
43. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
44. [Loss of heterozygosity fine mapping of chromosome 17p13 in transitional cell carcinoma of human urinary bladder].
Zheng S; Zhang J; Di X; Xiao Z; Wang D; Li C; He Z; Han N; Guo S; Cheng S; Gao Y
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):161-3. PubMed ID: 11953150
[TBL] [Abstract][Full Text] [Related]
45. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
47. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
48. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder.
Keen AJ; Knowles MA
Oncogene; 1994 Jul; 9(7):2083-8. PubMed ID: 8208555
[TBL] [Abstract][Full Text] [Related]
49. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder.
Cheng L; MacLennan GT; Zhang S; Wang M; Pan CX; Koch MO
Cancer; 2004 Jul; 101(1):183-8. PubMed ID: 15222005
[TBL] [Abstract][Full Text] [Related]
50. Karyotypic characterization of urinary bladder transitional cell carcinomas.
Fadl-Elmula I; Gorunova L; Mandahl N; Elfving P; Lundgren R; Mitelman F; Heim S
Genes Chromosomes Cancer; 2000 Nov; 29(3):256-65. PubMed ID: 10992300
[TBL] [Abstract][Full Text] [Related]
51. Allelotype of head and neck squamous cell carcinoma.
Nawroz H; van der Riet P; Hruban RH; Koch W; Ruppert JM; Sidransky D
Cancer Res; 1994 Mar; 54(5):1152-5. PubMed ID: 8118797
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.
Tomizawa Y; Adachi J; Kohno T; Hamada K; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Yokota J
Clin Cancer Res; 1999 May; 5(5):1139-46. PubMed ID: 10353749
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer.
Ploussard G; Dubosq F; Soliman H; Verine J; Desgrandchamps F; De Thé H; Mongiat-Artus P
Urology; 2010 Aug; 76(2):513.e13-8. PubMed ID: 20605198
[TBL] [Abstract][Full Text] [Related]
54. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
55. Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology.
Babu VR; Lutz MD; Miles BJ; Farah RN; Weiss L; Van Dyke DL
Cancer Res; 1987 Dec; 47(24 Pt 1):6800-5. PubMed ID: 3479251
[TBL] [Abstract][Full Text] [Related]
56. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.
Yamamoto Y; Matsuyama H; Furuya T; Oga A; Yoshihiro S; Okuda M; Kawauchi S; Sasaki K; Naito K
Clin Cancer Res; 2004 Oct; 10(19):6449-55. PubMed ID: 15475431
[TBL] [Abstract][Full Text] [Related]
57. Allelic imbalance on chromosomes 3p, 9p and 17p in malignant progression of laryngeal mucosa.
Guo T; Sun JW; Lv QP; Li XG
J Laryngol Otol; 2008 Jan; 122(1):72-7. PubMed ID: 17498326
[TBL] [Abstract][Full Text] [Related]
58. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer.
Merlo A; Gabrielson E; Mabry M; Vollmer R; Baylin SB; Sidransky D
Cancer Res; 1994 May; 54(9):2322-6. PubMed ID: 8162574
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
[TBL] [Abstract][Full Text] [Related]
60. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
